Identifying genomic changes and therapeutic vulnerabilities in neuroblastoma

Research Overview

Neuroblastoma is the most common extra cranial solid tumor in children. Less than 50% of patients with high-risk neuroblastoma will survive long-term with current therapies, and survivors are at risk for serious treatment-related late toxicities.  The goal of the lab is to discover new therapeutic targets and biomarkers to risk stratify patients and guide therapy selection. To accomplish this, research in the lab focuses on understanding the underlying genomic abnormalities in high-risk neuroblastoma.

Functional Genomics

We use a variety of next-generation approaches to decipher the cancer genome.


Selected Metrics

Lab members